(Total Views: 399)
Posted On: 10/08/2024 1:14:04 AM
Post# of 154120
FcRn LS in our Covid patent:
In some embodiments, the mutated or variant Fc region portion exhibits increased binding to FcRn, FcγRI (CD64), FcγRIIA (CD32), FcγRIIIA (CD16a), FcγRIIIB (CD16b), or any combination thereof. In some embodiments, the Fc region portion in an antibody or antigen-binding fragment of the present disclosure is a variant Fc region portion having increased ADCC, CDC, half-life, or any combination thereof.
https://patents.justia.com/patent/11045546
____
Imbodiment descriptions of increased & decreased FcRn binding scenarios.
Looks at least to me, our Covid patent qualifies our LL-PLS, as a pateng extention.
In some embodiments, the mutated or variant Fc region portion exhibits increased binding to FcRn, FcγRI (CD64), FcγRIIA (CD32), FcγRIIIA (CD16a), FcγRIIIB (CD16b), or any combination thereof. In some embodiments, the Fc region portion in an antibody or antigen-binding fragment of the present disclosure is a variant Fc region portion having increased ADCC, CDC, half-life, or any combination thereof.
https://patents.justia.com/patent/11045546
____
Imbodiment descriptions of increased & decreased FcRn binding scenarios.
Looks at least to me, our Covid patent qualifies our LL-PLS, as a pateng extention.
(0)
(0)
